Precision oncology company developing targeted cancer therapies based on synthetic lethality.
IDEAYA Biosciences, Inc. is a precision medicine oncology company with a focus on synthetic lethality, dedicated to discovering and developing targeted therapeutics tailored to patient populations identified through molecular diagnostics.
At the forefront of its pipeline are innovative product candidates. IDE397, currently in Phase I clinical trials, is a methionine adenosyltransferase 2a inhibitor designed for patients with solid tumors characterized by methylthioadenosine phosphorylase deletions. IDE196, another lead candidate, is a protein kinase C inhibitor undergoing Phase I/II clinical trials for genetically defined cancers with GNAQ or GNA11 gene mutations.
In addition to its clinical candidates, IDEAYA Biosciences boasts a robust preclinical pipeline. This includes synthetic lethality programs targeting PARG inhibitors for tumors with specific biomarkers linked to genetic mutations or molecular signatures, Pol Theta inhibitors for tumors exhibiting BRCA or other homologous recombination deficiencies, and WRN inhibitors for tumors demonstrating high microsatellite instability.
Established in 2015 and headquartered in South San Francisco, California, IDEAYA Biosciences collaborates extensively within the scientific community. The company has entered into a research collaboration with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA has formed a clinical trial collaboration and supply agreement with Pfizer Inc. for a Phase I/II study targeting metastatic uveal melanoma, skin melanoma, and other solid tumors, in addition to a strategic partnership with GlaxoSmithKline plc, underscoring its commitment to advancing innovative oncology treatments.